You are viewing just a glimpse of the 100+ pieces of sophisticated insight and analysis produced by our full-time team of senior financial journalists every day. For full access, check to see if your firm has a license to The Deal Pipeline or login using your existing credentials.
Published March 12, 2009 at 9:43 AM
Pfizer Inc. hopes to close its $68 billion deal to buy Wyeth by the end of 2009. To get there it will have to pass muster with antitrust regulators and credit agencies. Then the real work of integration begins. In this edition of Inside the Deal, Robbert Van Batenburg, head of equity research for Louis Capital Markets, tells Suzanne Stevens that the stakes for both companies are high. But with its patent on the blockbuster Lipitor set to expire in 2010 and a limited pipeline to offset the loss, the risks of the deal collapsing would be particularly damaging for Pfizer.
Leezie Kim is rejoining the Phoenix office of Quarles & Brady LLP as a partner. She will continue her corporate transactions practice. For other updates launch today's Movers & shakers slideshow.
Dechert's Henry Nassau at the 18th annual Wharton Private Equity and Venture Capital Conference tells The Deal Pipeline how to shine in the middle market. More video
Search
